資源描述：
《不同方案治療晚期非小細(xì)胞肺癌的近期療效觀察》由會員上傳分享，免費在線閱讀，更多相關(guān)內(nèi)容在工程資料-天天文庫。
1、不同方案治療晚期非小細(xì)胞肺癌的近期療效觀察福建醫(yī)科大學(xué)教學(xué)醫(yī)院福州肺科醫(yī)院腫瘤內(nèi)科陳群石琴謝強(qiáng)李育宏林江平王成輝王琳摘要目的以吉西他濱聯(lián)合順鉗(GP)、長春瑞濱聯(lián)合順鉗(NP)及多西紫杉醇聯(lián)合順鈉(DP)等三種化療方案治療晚期非小細(xì)胞肺癌，評價近期療效和毒性。方法選擇ECOG計分W2,生存期超過三個丿J。WBC計數(shù)〉4.0X107L,肝腎功能正常，未有活動性感染征象。200例既往均未曾放療或化療，70例給予GP方案；70例給予NP方案，60例給予DP方案。結(jié)果GP組、NP組和DP組的RR%分別為45.7%和42.9%和43.3%,三組間無統(tǒng)計學(xué)
2、差異?=0.136,P=0.934,(P>0.05)o三組3/4度不良反應(yīng)發(fā)生率較總的不良反應(yīng)明顯減少，而且齊組的3/4度不良反應(yīng)無統(tǒng)計差異性。NP組局部反應(yīng)多見，DP組乏力較少，血液毒性方面GP組的白細(xì)胞和NP組的血小板減少較明顯，GP組、NP組和DP組的一年生存率分別是40.0%、40.5%、38.3%,疾病進(jìn)展時間分別是4.9個月、5.1個月、4.6個月。結(jié)論新的含鉗二藥聯(lián)合方案GP、NP、DP高效、安全，是非小細(xì)胞肺癌一線標(biāo)準(zhǔn)方案的良好選擇。關(guān)鍵詞非小細(xì)胞肺癌；化學(xué)療法；吉西他濱；長春瑞濱；多西紫杉醇；順鈾；Toobservetheev
3、aluateofthreekindsofchemotherapyinthetreatmentofadvancednon-smallcellcancerCHENqun，SIqing，XIEqiang,LIyuhong,LINjiangping,WANGchenhui9WANGlin.Departmentoftomour,FuzhouPulmonaryHospitalofFujianmedicalcollegeteachinghospital,Fuzhou350008,China.[Abstract]ObjectiveToevaluatetheef
4、ficacyandtoxicityofgemcitabinepluscisplatin(GP),vinorelbinepluscisplatin(NP)anddocetaxelpluscisplatin(DP)inthetreatmentofadvancednon-small-celllungcancer(NSCLC).Methods200patientswithECOG<2point,survivaltimemorethanthreemonths,countsofWBC>4.0x109/L,functionofliverandkidneyar
5、enormal,noinfectsymptom.nevertreatedpreviouslywithradiotherapyandchemotherapy.Inthat,70patientstreatedwithgemcitabinepluscisplatin(GP),70patientstreatedwithvinorelbinepluscisplatin(NP)and60patientstreatedwithdocetaxelpluscisplatin(DP)?ResultsTheoverallresponserates(RR)were45
6、.7%inthegroupGP,42.9%inthegroupNPand43.3%inthegroupDP.Itwasnostatisticaldefenebetweenthreekindsofchemotherapy(x2=0.136,P=0.934,P>0.05).TheIII?IVdegreetoxicitywerelessthantotaltoxicity,andindistinguishablybetweenthethreegroups(P>0.05).LocalresponseinthegroupNPwasmorethananthe
7、rgroups.LeucocyteofthegroupNPandplateletofthegroupGPweredecreaseevidence.TheweakinthegroupDPwaslesseeTheYearSurvivalRatewere40.0%inthegroupGP,40.5%inthegroupNPand38.3%inthegroupDP.TheTimeToProgresswere4.9monthsinthegroupGP,5.1monthsinthegroupNPand4.6monthsinthegroupDP.Conclu
8、sionNewplatinum-basedcombinechemotherapy，suchastheGP，DPandtheNPhadhighereff
